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Abstract
Fragile X is the most common inherited cause of mental retardation with a prevalence of 1 in 4000 
for males and 1 in 5000 to 8000 for females. The American College of Medical Genetics and 
Genomics has recommended diagnostic testing for fragile X in symptomatic persons, women with 
ovarian dysfunction, and persons with tremor/ataxia syndrome. Although medical and scientific 
professionals do not currently recommend screening nonsymptomatic populations, improvements 
in current treatment approaches and ongoing clinical trials have generated growing interest in 
screening for fragile X. Here, we briefly review the relevant molecular basis of fragile X and 
fragile X testing and compare three different molecular technologies available for fragile X 
screening in both males and females. These technologic approaches include destabilizing the 
CGG-repeat region with betaine and using chimeric CGG-targeted PCR primers, using heat pulses 
to destabilize C-G bonds in the PCR extension step, and using melting curve analysis to 
differentiate expanded CGG repeats from normals. The first two-step method performed with high 
sensitivity and specificity. The second method provided agarose gel images that allow 
identification of males with expanded CGG repeats and females with expanded CGG-repeat bands 
which are sometimes faint. The third melting curve analysis method would require controls in 
each run to correct for shifting optimal cutoff values.
Reduction of the protein coded for by the fragile X mental retardation gene (FMR1) causes 
fragile X syndrome, a genetic condition that causes a range of developmental problems, 
including learning disabilities, cognitive impairment, and behavioral abnormalities.1 
Expansion of CGG repeats in the 5′ untranslated region (UTR) of the FMR1 gene is 
associated with hypermethylation and inactivation of gene expression (Figure 1).
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Function of the FMR1 Gene
Evidence suggests that the protein coded for by the FMR1 gene on the long arm of 
chromosome X (Xq27.3) binds mRNA and associates with polyribosomes in neurons.2 The 
protein likely shuttles mRNA from the nucleus through the cytoplasm and localizes 
dendritic mRNA where it represses synaptic protein synthesis. After the group 1 
metabotropic glutamate receptor is stimulated, regulatory FMR1 protein (FMRP) production 
is believed to repress mRNA translation and protein synthesis and to control permanent 
physical changes that alter synaptic connections linked with the process of learning and 
memory.3–6
Mutations and Associated Conditions
Normal Range
Greater than 99% of fragile X cases are caused by expansions of CGG repeats in the FMR1 
5′ UTR.7 The other 1% is caused by a variety of other mutations, primarily including gross 
deletions and duplications, regulatory mutations, and missense and nonsense mutations. The 
CGG-repeat numbers of individual genes have been categorized, and the borders of these 
categories are approximate. The normal range of CGG repeats is considered generally to be 
as high as 44 CGG repeats, and these repeats are interrupted typically every 9 or 10 repeats 
by an AGG triplet. These AGG triplets likely anchor the region and prevent slippage during 
DNA replication. The number and spacing of AGG triplets within CGG-repeat regions may 
help predict risk of expansion of <100 repeats.8
Gray Zone (Intermediate Range)
The range of 45 to 54 CGG repeats is referred to as the gray zone or intermediate range; for 
alleles of this size, neither disease associations nor the rate of expansion are fully 
understood. However, this range is not associated with fragile X syndrome, and gray zone 
alleles expanding to a full mutation in one generation have not been observed.7
Premutation Range
Alleles with approximately 55 to 199 CGG repeats are considered premutations. These 
alleles are transmitted unstably from parent to child, and expansions from this range to the 
full-mutation range typically occur during maternal transmission. Because mutations of this 
size possibly can have somatic mosaicism that includes a full mutation, careful examination 
of the range of allele sizes is warranted.7 The smallest FMR1 premutation that was reported 
to expand to a full mutation (to approximately 538 CGG repeats) in a single generation is 56 
CGG repeats. In addition in this case, two AGG interruptions in the grandfather’s gray zone 
allele of 52 CGG repeats were absent when transmitted to his daughter.9
Expansion of an allele into the premutation range perturbs gene expression,7 and two 
conditions are associated with this range of expansions. Reductions in FMRP occur in this 
range and are associated with increased FMR1 mRNA. Premutation alleles may shift 
transcription of the FMR1 mRNA to an upstream site, and this use of an alternative start site 
may correlate with increased transcription levels. This RNA-mediated toxicity is associated 
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with fragile X-associated tremor/ataxia syndrome,10,11 a late-onset, progressive 
development of intention tremor and ataxia frequently accompanied by cognitive and 
behavioral difficulties. Although most persons with pre-mutations do not show fragile X-
related features, females with premutations generally >80 CGG repeats are at approximately 
20% risk of fragile X-associated premature ovarian insufficiency.7 Older males and females 
with premutations are at risk of fragile X-associated tremor/ ataxia syndrome, with higher 
risk in males. The penetrance of fragile X-associated tremor/ataxia syndrome increases with 
age and CGG repeat length.
Full Mutations
Expansion of CGG repeats to >200 results in full mutations.7 Full mutations typically range 
from several hundred to several thousand CGG repeats. Hypermethylation is present 
typically on most or all DNA copies except DNA extracted from chorionic villus sampling; 
hypermethylation results typically in lower or no production of FMRP. Relatively small 
studies have indicated that, when a full mutation on the single X chromosome in males is 
completely methylated, the most severe form of fragile X results.12 Methylation of large 
CGG expansions can vary, however, leading to variable phenotypes. Females have two X 
chromosomes; during normal development, one is methylated randomly and inactivated in 
different tissues. Therefore, females with full mutations may experience a range of 
symptoms, depending on whether a normal-X allele or the full-mutation allele is active in a 
specific tissue.
For full mutations, size mosaics of CGG repeats and methylation mosaics are observed. 
Analysis of full mutations typically indicates that multiple sizes of CGG repeats are present. 
Tissue-specific differences can be seen, and persons with size and methylation mosaicism 
may be higher functioning than persons with completely methylated full mutations.7
Other Mutations in the FMR1 Gene
Currently, the Human Gene Mutation Database Professional 2014.3 Free version (http://
www.hgmd.cf.ac.uk/ac/index.php, last accessed November 17, 2014)includes 65known 
mutations in the FMR1 gene, including the CGG repeat variations in the 5′ UTR. Almost all 
mutations are associated with fragile X and its related conditions, developmental delay, 
neurodevelopmental dysfunction, intellectual disability, or syndromic mental retardation. 
Mutations other than expanded CGG repeats are estimated to cause <1% of fragile X.7 More 
than one-half of these additional mutations are gross deletions (n = 33). These generally 
range from several hundred base pairs to millions of base pairs and frequently include the 
entire FMR1 gene. The next most common nonrepeat mutations are regulatory mutations (n 
=6). These are point mutations 83 to 332 bp upstream of the initiation codon (n =4) and 760 
to 1174 bp downstream of thetermination codon (n =2). Next most common mutations are 
gross duplications (n =5). All but one include duplication of the entire FMR1 gene. Four 
point mutations include three missense mutations (p.Arg138Gln, c.413G>A; p.Ile304Asn, c.
911T>A; and p.Leu578Phe, c.1732C>T) and one nonsense mutation (p.Ser27Term, c.
80C>A). The remaining nonrepeat mutations include two small deletions, one splicing 
mutation, one small insertion/deletion, and one complex rearrangement.
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Approaches to Detecting FMR1 Mutations
Detecting FMR1 Mutations Clinically
The American College of Medical Genetics and Genomics has recommended diagnostic 
testing for fragile X in symptomatic persons, women with ovarian dysfunction, and persons 
with tremor/ataxia syndrome, and the Committee on Genetics of the American Academy of 
Pediatrics has recommended testing for fragile X in all persons with intellectual disability 
for whom there is no strongly suspected diagnosis.13,14 Fragile X and CGG repeat 
abnormalities are also a heritable cause of approximately 0.46% to 2% of autism.15,16 
Chromosomal microarray analysis, a method that detects submicroscopic genomic deletions 
and duplications, is used commonly to test for autism, but it does not detect fragile X. The 
methods for measuring and estimating CGG repeats clinically include Southern blot analysis 
for size and methylation estimation.7,17–20 In addition, PCR methods were developed to 
screen for and to clinically diagnose fragile X. Widely used commercial reagents allow the 
following: i) PCR amplification and quantification of normal and gray zone CGG repeats, ii) 
amplification and verification of premutations and full mutations by using CGG repeat-
targeted primers, iii) determination of methylation with methylation-specific PCR, and iv) 
identification of AGG interruptions to help assess risk of expansion of < 100 CGG 
repeats.8,21–25
Sequencing FMR1
Although the coding portion of the FMR1 gene can be sequenced by conventional methods, 
the tri-nucleotide repeats in the 5′ UTR can approach 100% CG content, depending on the 
number of AGG interruptions. The tight binding of CG-rich regions causes difficulty in 
sequencing. The longer the CGG repeat, the more difficult it is to sequence, particularly in 
the full-mutation range. This means that expanded CGG repeats cannot be sequenced with 
conventional Sanger sequencing or commonly used next-generation sequencers. However, a 
new technology, single-molecule real-time sequencing, that may provide a means of better 
estimating the number of expanded CGG repeats in the future was reported recently.26
Detecting Deletions and Duplications
Gross deletions and insertions or duplications account for 38 of the 65 currently known 
mutations in FMR1 (Human Gene Mutation Database Professional 2014.3, available at 
http://www.hgmd.cf.ac.uk/ac/index.php, last accessed November 17, 2014). Methods that 
detect these types of mutations include Southern blot analyses, SALSA multiplex ligation-
dependent probe amplification assay (MRC Holland MLPA, Amsterdam, the Netherlands), 
and comparative genomic hybridization array analysis.
Screening for Expanded CGG Repeats
The estimated prevalence of males with full mutations is approximately 1 in 4000; 
prevalence of females with full mutations is approximately 1 in 5000 to 8000.7 All major 
ethnic groups and races appear to be susceptible to expansion of CGG repeats in FMR1. 
Although varying prevalences in different ethnic groups occur, few ethnicities have a higher 
prevalence than the white population. Because of this relatively high prevalence in different 
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ethnicities, improvements in current treatments, and several ongoing clinical trials that are 
evaluating agents to ameliorate or prevent the damage that occurs in fragile X (Clinical 
Trials available at http://www.nichd.nih.gov/health/topics/fragilex/clinicaltrials/Pages/
default.aspx, last accessed May 2, 2014; FRAXA Research Foundation Clinical Trials 
available at: http://www.fraxa.org/toward-a-cure/clinical-trials, last accessed June 19, 2014), 
a growing interest exists in screening for expanded CGG repeats in FMR1.
In addition to methods that use Southern blot analysis, researchers have taken different 
technical approaches to screening for fragile X. Although commercial reagents are used for 
testing and screening in a clinical setting, in the newborn screening (NBS), public health 
setting NBS programs test every baby born in the United States and in other countries. The 
cost per test must be manageable for states with varying resources. Ideally, the supplies and 
reagents for a first-tier NBS test should cost ≤ $5 per test, and fragile X commercial reagent 
kits have higher costs. Various technical approaches to screening large populations target 
expanded CGG repeats, methylation of the promotor region, or FMRP itself.
Some techniques that detect fragile X in males are not able to detect full mutations reliably 
in females. These methods include an assessment of FMR1 methylation in DNA isolated 
from dried blood spots, developed by Warren and colleagues,27 and a recent method that 
targets FMRP detection by using an immunoassay with a novel standard.28 Although both of 
these techniques identify males with fragile X, they cannot reliably detect females with full 
mutations because of either the complexities of random X-methylation and inactivation or 
the overlap of normal FMRP levels in females with FMRP levels of females with full 
mutations on one X chromosome.
Several molecular techniques were published that attempt to detect both males and females 
with expanded CGG repeats. These methods use different technical approaches to facilitate 
the PCR amplification of the tightly bound repeat region in the 5′ UTR of FMR1. To 
evaluate the feasibility of using low-cost molecular techniques to screen for fragile X, we 
chose three approaches to this challenging problem that use novel molecular methods that 
had i) the potential to detect expanded CGG repeats in both males and females, ii) a target 
instrument and reagent cost of approximately $5 per test, and iii) procedures that were more 
amenable to high throughput than Southern blot analyses and methylation determinations.
Materials and Methods
Samples
We used commercially available DNA samples (including normal blood bank samples) to 
evaluate normal samples from 37 males and 54 females (n = 91), samples from one male and 
two females with gray zone mutations (n = 3), and samples from 26 males (4 with 
premutations and 22 with full mutations) and 12 females (7 with premutations and 5 with 
full mutations) (n = 38). Coriell Institute for Medical Research (Camden, NJ) provided the 
samples with expanded CGG repeats and samples from 10 male and 20 female subjects who 
were tested psychologically and were found to be normal (n = 30). All sample classifications 
were verified with the clinical AmplideX reagents from Asuragen (Austin, TX). Fragile X 
controls were provided by Asuragen, and the World Health Organization standards were run 
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to validate all assays. For this study, we used DNA from commercial sources; thus, the work 
did not meet the definition of human subjects as specified in 45 CFR 46.102 (f).
Evaluation of Screening Methods
The first approach, developed by Tassone et al,29 uses betaine in the PCR master mix to 
amplify expanded FMR1 alleles in conjunction with a chimeric PCR primer that randomly 
targets the CGG region. This method uses a two-step screening strategy and can be used 
with DNA extracted from blood spots. In this procedure, a first round of PCR products are 
produced with sequence-based forward and reverse primers and are then analyzed by 
capillary electrophoresis (Figure 2A). Normal samples yield one or two normal 
chromatographic peaks for females and one normal peak for males. Samples that yield a 
single normal peak for females or no normal peak for males are tested again in a second 
round of PCR by using one sequenced-based primer and a chimeric primer that targets the 
CGG repeats (Figure 2B).
The second approach, developed by Orpana and coworkers, uses heat pulses in the PCR 
extension step that destabilize the tight C-G bonds.30 In the PCR extension step gradual 
heating precedes multiple rapid heat pulses that destabilize the secondary structures caused 
by intramolecular folding of the DNA template and re-annealing of PCR products (Figure 
3). Then the PCR products are analyzed with agarose gel electrophoresis, and length of the 
CGG repeat region is determined with standard molecular weight markers.
The third approach, developed by Teo et al,31 uses melting curve analysis on a real-time 
PCR instrument to detect FMR1 expansions in males and females. This approach consists of 
two complementary FMR1 triplet-primed PCR assays in the 3′ and 5′ directions (Figure 4). 
The 3′ and 5′ PCRs are performed separately under identical thermal cycling conditions in 
the LightCycler Real-Time PCR System (Roche Applied Science, Indianapolis, IN). The 
amplicons are melted after the thermocycling program is completed, and then the first 
derivative melting curves are analyzed. This method ascertains whether the temperature at 
which the first derivative melting curve returns to baseline is above or below a cutoff to 
distinguish premutations and full mutations from normal alleles. Gray zone mutations may 
fall in either category, and this method cannot identify them specifically.
Statistical Analysis
The estimates of sensitivities, specificities, and 95% exact binomial CIs for those estimates 
were calculated with SAS version 9.3 (SAS Institute Inc., Cary, NC).
Results
Approximately 25% to 40% of the female population is homozygous for the same number of 
CGG repeats, so using the Tassone method a single normal peak for females analyzed with 
standard primers could indicate a homozygous female with two copies of the same normal 
repeat or a female with both a normal and a nonamplifying expanded CGG repeat. A male 
with no normal peak is likely to have an expanded CGG repeat. For expanded samples of 
males and females, the standard and chimeric primers produce a series of peaks of 
diminishing amplitude, referred to as a stutter, which extend beyond the normal range and 
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confirm the expanded repeat. When normal samples are tested with standard primers and the 
resulting fragments are analyzed by capillary electrophoresis, the Tassone method yields one 
or two peaks in the normal range for heterozygous females and one peak in the normal range 
for males (Figure 5A). CGG repeats in the gray zone amplify and appear in the appropriate 
window (Figure 5B). Usually, larger pre-mutations and full mutations do not amplify with 
the first step of this method (Figure 5C). Samples that have only one peak for females and 
no peak for males require analysis with CGG-targeted primers (Figure 5D); this analysis 
does not distinguish between premutations and full mutations.
We analyzed 91 normal samples, 3 gray zone mutations, and 38 premutations and full 
mutations and correctly categorized all samples except one female sample with a normal and 
an expanded allele [100% specificity (95% CI, 96.0%–100%) and 97.6% sensitivity (95% 
CI, 87.1%–100.0%)] (Table 1). The incorrect categorization of the one female sample with 
an expanded allele was a random error; a repeat analysis correctly identified this sample. 
Identification of the expanded alleles depends on the stutter that results from the CGG-
targeted PCR extending beyond the normal repeat range.
When normal alleles are present with the Orpana method, a distinct band is evident on the 
agarose gel (Figure 6). This method works well for males with premutations and full 
mutations because no normal band is present (Figure 6A) even if an expanded allele is not 
evident. Therefore, for males we correctly identified all normal samples and all samples with 
premutations and full mutations (Table 1). Quantitating gray zone mutations is difficult for 
males and females because of the resolution of the gels. In female samples the normal 
expected band can out-compete the expanded allele in the PCR (Figure 6B). Large expanded 
alleles in female samples may be faint, and the sensitivity and specificity will depend on the 
analyst’s ability to distinguish the faint expanded alleles from normal background in that 
region. We detected expanded bands for 10 of 12 female premutation and full mutation 
samples. Overall specificity and sensitivity estimates for the Orpana method, excluding gray 
zone CGG repeats, are 100% specificity (95% CI, 96.0%–100%) and 94.7% sensitivity 
(95% CI, 82.2%–99.4%).
We obtained characteristic first-derivative melting curves for normal and expanded alleles 
with the Teo method (Figure 7), and the sensitivity and specificity of the allele 
characterization depended on the cutoffs used (Figure 8). Only 81 normal, 3 gray zone 
samples, and 25 premutation and full mutation samples could be run by this method because 
of the availability of the loaned instrument. All premutations and full mutations tested 
positive by using the more robust 3′ assay and a cutoff of 91°C (Table 1). Under these 
conditions, we called one gray zone negative, one positive, and we could not call the third 
because it returned to baseline too close to the cutoff line. The Teo method does not claim to 
distinguish gray zone samples from normal or premutations and full mutations. At this 
cutoff four of the normal samples tested positive, including three males and one female. Of 
these false positives, two males and one female had alleles with CGG repeats in the high 
normal range from 41 to 44, and the remaining normal male had 36 CGG repeats. With the 
use of a cutoff of 91.0°C for the more robust 3′ assay, the specificity and sensitivity 
estimates for the Teo method are 95.1% specificity (95% CI, 87.8%–98.6%) and 100.0% 
sensitivity (95% CI, 86.3%–100.0%) for premutations and full mutations.
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Studies of population screening for fragile X conducted in a variety of settings have been 
systematically reviewed.32 Of the studies that met the inclusion criteria for the review, most 
prevalent were studies of women of reproductive age and of newborns. Studies were 
included when screening was offered to a general population and when psychosocial aspects 
of population screening of fragile X were addressed. Of the 11 studies that offered 
population screening, all but one screened women of reproductive age to determine whether 
they carried an expanded CGG repeat allele. The screening methods used relied on various 
combinations of PCR and Southern blot analysis, and one study quoted a cost of $100 per 
test. Southern blot analysis is too labor intensive and costly to be appropriate for NBS. Only 
one study offered NBS, and parents were only offered the option of testing their male 
newborns because the method used resulted in unreliable results in samples from females.
A recurrent theme across screening studies of women was the need for information and 
counseling because few participants had heard of fragile X before being offered screening 
and struggled to understand the clinical features of the disease.32 Although screening 
women of reproductive age was well received and early knowledge of the potential to 
develop fragile X-associated premature ovarian insufficiency was valued by women, 
screening of newborns was more contentious because the benefits of early intervention have 
not been established. Complex ethical and policy issues need to be resolved before 
mandated NBS is likely to be recommended. These issues include whether to screen only 
boys or both sexes, how to deal with incidental chromosomal findings, and whether to report 
only full mutations to parents or premutation expansions as well, which have adult-onset 
implications. The authors of the review by Hill et al32 recommend research to address these 
issues, in addition to further clinical trials to establish the benefit of early interventions.
Of the three molecular screening methods potentially appropriate for NBS that we evaluated 
in samples of males and females, the Tassone method achieved high sensitivity and 
specificity for all samples tested. The Orpana method works particularly well for male 
samples. Expanded alleles in females can be faint and more difficult to detect and are best 
evaluated by an analyst experienced in reading gels. Appropriate cutoff temperatures for the 
Teo method were not consistent from laboratory to laboratory or even from run to run in our 
laboratory. This circumstance would not allow establishing a universal cutoff and would 
necessitate using controls in each run to detect shifts in temperature cutoffs. Of the two Teo 
assays, we obtained the most robust performance with the 3′ assay.
In NBS one central laboratory usually performs screening for large populations. California 
has approximately 500,000 births per year and has several contract laboratories to perform 
this function. In other states one laboratory performs all of the analyses for one or more 
states, and the sample throughput demand can be quite high. The reagent, supply, and 
instrument cost per test is important with a goal of approximately ≤$5 per test to 
accommodate state NBS programs with varying financial resources. To determine whether 
these methods would be applicable to NBS laboratories, we estimated the cost of supplies 
and reagents for each screening method with amortization of major equipment over 5 years 
and the assumption of 55,602 samples per year, which was the median 2010 annual number 
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of births by state in the United States. Assuming operation 52 weeks per year and 5 days per 
week, approximately 214 samples would be analyzed per day. This is a feasible number for 
each of these methods with the specified equipment. The estimated cost does not include 
labor. The Tassone method cost of $4.25 per sample and includes the forward and reverse 
primer assays and the CGG-targeted assay when needed. This method uses the ABI 3730 
capillary electrophoresis DNA analyzer and the estimate assumes four thermal cyclers for 
this throughput. The Orpana method cost of $2.25 per sample includes the use of three gold 
block thermal cyclers. The Teo method cost of $5.71 per sample includes the use of the 
Roche LightCycler 480. In a high-throughput environment, the Tassone method has the 
advantage of potential automation of the PCR and capillary electrophoresis steps. Gel 
methods such as the Orpana method are less amenable to automation. In conclusion, in 
addition to available methods for clinical diagnosis of fragile X and its associated conditions 
in symptomatic persons,7,8,17–25 our study shows that there are appropriate methods to 
screen larger populations of males and females at low cost so that early interventions may 
help prevent or delay the disability of fragile X.
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Expansion of the CGG repeats in the 5′ untranslated region of the FMR1 gene on the X 
chromosome can result in decreased mRNA and FMRP production, causing fragile X. 
FMRP, FMR1 protein.
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Tassone fragile X screening method29: A: The first step uses sequence-based forward and 
reverse PCR primers to amplify the CGG repeat region fragments which are analyzed on an 
ABI 3730 capillary electrophoresis DNA analyzer. B: If there are less than two peaks for 
females or no peak for males, the forward primer is run with a CGG-targeted reverse primer 
with capillary electrophoresis analysis of the resulting fragments.
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The Orpana fragile X screening method29 uses multiple heat pulses in the PCR extension 
step to destabilize secondary structures and to enhance the extension over the GC-rich 
sequence of the CGG repeat region. The method uses agarose gel electrophoresis to detect 
the resulting amplicons.
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The Teo fragile X screening method31 uses a melting curve analysis of triplet-primed PCR 
products in the 5′ and 3′ directions. The repeat-annealing primers tail-CCGR and tail-CGGF 
anneal fully within the repeat sequence and are tailed at their 5′ ends with 
noncomplementary sequences to enhance the production of amplicons.
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Tassone method.29 A: A normal sample from a heterozygous female and a normal sample 
from a male analyzed with sequence-based forward and reverse primers. B: Samples from a 
female and male with a gray zone allele analyzed with sequence-based forward and reverse 
primers. C: A sample from a female with a normal 29 CGG-repeat allele and an expanded 
allele, and a sample from a male with an expanded CGG-repeat allele analyzed with 
sequence-based forward and reverse primers. D: Samples from a homozygous female with 
two normal 30 CGG-repeat alleles, a sample from a female with a normal and an expanded 
CGG allele, and a sample from a male with an expanded CGG allele run with a sequence-
based primer and a chimeric CGG-targeted primer.
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Orpana method.30 Agarose gels of amplicons generated by heat-pulse PCR from males (A) 
and females (B). The allele sizes are indicated above the tracks.
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Teo method.31 Melting curves from a normal sample from a female with 18 and 29 CGG 
repeats (A) and a full mutation sample from a female with 21 and 650 CGG repeats (B). The 
vertical reference lines represent cutoffs of 83.3°C for the 5′ assay and 91°C for the 3′ assay.
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Teo method.31 The sensitivity and specificity of the 3′ and 5′ assay at different temperature 
cutoffs.
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